“The medical preparation of the invention produces most unexpected and beneficial results, by for example alleviating fears and anxieties which may have been present in the patient”
1/12
The patents claimed medical preparations of:
(1) ibogaine, iboga alkaloid extract, or total extract; plus
(2) amphetamine, MDA, TMA, tetrahydronapthylamine, or naphazoline
“The best results have been obtained with” MDA
The combination “forms an excellent medicine"
2/12
The ibogaine “has the effect of considerably clarifying the mind of the sick person, giving him a kind of extra-lucid vision of his ‘ego.’ It likewise excites the memory centre of the brain thus revealing memories which may go back to a period before the age of 4…”
A primary difference between the new ‘257 & the first ‘175 patent is:
– ‘175 patent claims methods “of treating drug resistant depression” by orally administering “an oral dosage form“ of the COMP360 psilocybin Polymorph A
– ‘257 patent claims the “oral dosage form” itself
2/7
Just as with the first ‘175 patent, the new ‘257 patent claims the psilocybin Polymorph A by reference to its “XRPD diffractogram”
These are the peaks displayed when the polymorph is analyzed by X-ray
Compass unsuccessfully sought claims without these XRPD limitations
Compass is listed as collaborator on an investigator-initiated study at UC San Diego, to explore the safety, tolerability, & efficacy of psilocybin-assisted therapy for anorexia
Another study, sponsored by Imperial College London, will also assess the acceptability & efficacy of treating anorexia with psilocybin, & will use MRI & EEG to examine neuronal underpinnings of tx